Roche’s BTK inhibitor fenebrutinib posts Phase III MS win, overshadowed by deaths imbalance

Roche (SWX: RO; OTCQX: RHHBY) reported a strong Phase III efficacy win for fenebrutinib in relapsing multiple sclerosis, which cut annualized relapse rates by 51.1% and 58.5% versus teriflunomide across two studies. But the result was clouded by a notable safety signal: seven deaths in fenebrutinib-treated patients versus one on teriflunomide during the reporting period, a disparity likely to become the main focus of regulatory and investor scrutiny. Roche has nonetheless submitted the BTK inhibitor to global regulators based on the benefit-risk profile rather than efficacy alone.

The FENhance 1 and 2 program is a pair of Phase III multicenter, randomized, double-blind, double-dummy, parallel-group studies enrolling a combined 1,497 adults with RMS, each running for at least 96 weeks against teriflunomide as the active comparator.

Across both studies, fenebrutinib met the primary endpoint of annualized relapse rate with reductions of 51.1% (p<0.001) in FENhance 1 and 58.5% (p<0.0001) in FENhance 2. On MRI secondary endpoints, new T1 gadolinium-enhancing lesions fell by 70.7% and 77.6%, respectively, and new or enlarging T2 lesions by 76.0% and 82.5% (all p<0.0001). Disability progression trended in favor of fenebrutinib — a 20% and 13% reduction in 12-week composite confirmed disability progression — but confidence intervals crossed 1.0 in both studies, leaving those findings directional rather than conclusive.

The efficacy win was overshadowed by a notable mortality imbalance that is likely to draw close regulatory scrutiny. Seven deaths (0.9%) occurred in the fenebrutinib arms across FENhance 1 and 2 during the reporting period, versus one (0.1%) in the teriflunomide arms, with causes including cryptococcal infection, pneumonia, serious bleeding, and suicide. Serious adverse events were broadly comparable in FENhance 1 (8.6% vs 8.9%) but diverged in FENhance 2 (11.2% vs 6.1%). Liver enzyme elevations above three times the upper limit of normal were similar between arms in both studies, and one Hy's Law case appeared in each treatment group in FENhance 1, both resolving after discontinuation.

Fenebrutinib is an oral, CNS-penetrant, reversible non-covalent BTK inhibitor designed to act on two distinct cell populations: peripheral B cells, which drive the acute inflammatory relapses characteristic of RMS, and microglia within the CNS, which are implicated in the chronic smoldering pathology thought to underlie progressive disability. That dual targeting distinguishes it mechanistically from teriflunomide, which suppresses lymphocyte proliferation through DHODH inhibition without direct CNS penetration, and from anti-CD20 therapies such as ocrelizumab (Ocrevus), which deplete B cells systemically but do not cross the blood-brain barrier. Whether microglial inhibition translates into a meaningful disability benefit in RMS remains an open question given the non-significant progression data from FENhance. Cross-trial comparisons are limited by differences in patient populations, trial design, and follow-up duration.

The competitive context matters here. Sanofi's tolebrutinib, another BTK inhibitor, showed a 29.9% ARR reduction versus teriflunomide in its GEMINI trials — a smaller effect than fenebrutinib's reported reductions, though the programs differ in design and patient selection. Roche also reported previously that fenebrutinib met non-inferiority to ocrelizumab in the Phase III FENtrepid study in primary progressive MS, making it potentially the first oral agent with Phase III data across both RMS and PPMS. Roche said it will submit the totality of data from all three pivotal studies to regulatory authorities.

---

Spot something wrong? Report an issue with this article